The Molecular Cytogenetics Core provides valuable scientific and technical support to MSK investigators exploring the role of chromosomal instability in cancer. This is accomplished through appropriate and efficient experiment design, custom multi-color DNA-FISH probe design and development, data analysis and interpretation, and support with manuscript/grant preparation. Currently, the Core provides 2 main categories of specialized service that operate at the single-cell level on a variety of human and animal model research samples: conventional karyotyping and fluorescence in situ hybridization (FISH). Conventional karyotyping is routinely performed to confirm cell line identity, screen targeted mouse ESC clones intended for blastocyst injection, monitor the stability of cultured stem cells over time, and measure chromosomal instability/heterogeneity as an experimental endpoint. Over the years, the Core has assembled a broad range of molecular cytogenetics resources (plasmids, BAC clones, individual whole chromosome painting probes), allowing the Core to provide FISH services at significantly lower cost. FISH-based assays are routinely employed to map genes or transgene integration sites, detect aneuploidy/chromosomal instability, co-detect DNA/protein and assess intra-tumoral heterogeneity; tests include custom probe development, locus-specific FISH, whole-chromosome painting (WCP), spectral karyotyping (SKY), Q-FISH, and Immuno-FISH. The Core is equipped with 5 modern Fluorescence imaging systems including 2 with a wide range of applications that can be fully or partially automated. The Core also provides training in tissue culture, karyotyping, and FISH. During the past grant period, the services and collaborative work provided by the Molecular Cytogenetics Core have supported the research of 84 investigators from 8 research program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Choi, Karmel W; Shaffer, Kelly M; Zale, Emily L et al. (2018) Early Risk and Resiliency Factors Predict Chronic Posttraumatic Stress Disorder in Caregivers of Patients Admitted to a Neuroscience ICU. Crit Care Med 46:713-719
Kantor, Elizabeth D; Newton, Christina C; Giovannucci, Edward L et al. (2018) Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 29:389-397
Mizrachi, Aviram; Migliacci, Jocelyn C; Montero, Pablo H et al. (2018) Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution. Oral Oncol 78:94-101
Fassel, Hannah; Bussel, James B; Roberts, Stephen S et al. (2018) Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. J Pediatr Hematol Oncol :
Lezcano, Cecilia; Shoushtari, Alexander N; Ariyan, Charlotte et al. (2018) Primary and Metastatic Melanoma With NTRK Fusions. Am J Surg Pathol 42:1052-1058
Bello, Danielle M; Russell, Christy; McCullough, Debbie et al. (2018) Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology. Ann Surg Oncol 25:2884-2889
Coriddi, Michelle; Kenworthy, Elizabeth; Weinstein, Andrew et al. (2018) The importance of indocyanine green near-infrared fluorescence angiography in perfusion assessment in vascularized omentum lymphatic transplant. J Surg Oncol 118:109-112
Korenstein, Deborah; Husain, Solomon; Gennarelli, Renee L et al. (2018) Impact of Clinical Specialty on Attitudes Regarding Overuse of Inpatient Laboratory Testing. J Hosp Med 13:844-847
Wang, Lucia; Guillen, Valeria S; Sharma, Naina et al. (2018) New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. ACS Med Chem Lett 9:803-808
Offin, Michael; Rizvi, Hira; Tenet, Megan et al. (2018) Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res :

Showing the most recent 10 out of 8799 publications